HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial

1. Llombart-Cussac, A.
2. Cortés, J.
3. Paré, L.
4. Galván, P.
5. Bermejo, B.
6. Martínez, N.
7. Vidal, M.
8. Pernas, S.
9. López, R.
10. Muñoz, M.
11. Nuciforo, P.
12. Morales, S.
13. Oliveira, M.
14. de la Peña, L.
15. Peláez, A.
16. Prat, A.